Patients with myelodysplastic syndrome/acute myeloid leukemia
Patients may not have features suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicated
Patients must not have treatment-related acute myeloid leukemia (AML) (t-AML)/myelodysplastic syndrome (MDS) or features suggestive of AML/MDS
Patients must be suspected to have previously untreated acute myelogenous leukemia (AML) or myelodysplastic syndrome with excess blasts-2 (MDS-EB-2)
Patients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML
No features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) on peripheral blood smear
Participants with a previously documented diagnosis of myelodysplastic syndrome (MDS) (or any dysplastic leukocyte morphology suggestive of MDS) or acute myeloid leukemia
Patients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML
Patients with prior myelodysplastic syndrome or acute myeloid leukemia
No features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) on peripheral blood smear
Patients with hematologic malignancies (includes patients with myelodysplastic syndrome/acute myeloid leukemia)
Subjects with any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
Participants with a history of myelodysplastic syndrome or acute myeloid leukemia
Patients with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) on peripheral blood smear
Subjects with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of \r\nmyelodysplastic syndrome (MDS)/acute myeloid leukemia (AML).
Patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML), or features suggestive of MDS/AML
Known history or current diagnosis of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
Myelodysplastic features on peripheral blood smear
Within 7 days prior to administration of study treatment: No features suggestive of myelodysplastic syndrome/acute myeloid leukemia on peripheral blood smear.
A diagnosis or suspicion of myelodysplastic syndrome/acute myeloid leukemia.
Patient must not have any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
Known myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML)
Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of MDS/AML
Patients with myelodysplastic syndrome/acute myeloid leukemia
Patients may not have features suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicated
Patients with myelodysplastic syndrome/acute myeloid leukemia
Known history or current diagnosis of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
PHASE I AND II SCLC AND UROTHELIAL CARCINOMA EXPANSION COHORT: Patients with myelodysplastic syndrome/acute myeloid leukemia or pneumonitis; or baseline features suggestive of myelodysplastic syndrome or acute myelogenous leukemia on peripheral blood smear or bone marrow biopsy, if clinically indicated
PHASE I: No features suggestive of myelodysplastic syndrome/ acute myeloid leukemia
PHASE II: No features suggestive of myelodysplastic syndrome/ acute myeloid leukemia
No features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) on peripheral blood smear (measured within 28 days prior to administration of study treatment)
Patients with myelodysplastic syndrome/acute myeloid leukemia
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nNo baseline features suggestive of myelodysplastic syndrome or acute myelogenous leukemia on peripheral blood smear or bone marrow biopsy, if clinically indicated
PHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nNo baseline features suggestive of myelodysplastic syndrome or acute myelogenous leukemia on peripheral blood smear or bone marrow biopsy, if clinically indicated
No features suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicated
Patients with biopsy-proven acute myeloid leukemia or myelodysplastic syndrome with persistent disease or in remission
History or current diagnosis of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic Syndromes (MDS)/acute myeloid leukemia (AML).
Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
Patients with myelodysplastic syndrome/acute myeloid leukemia
Patients with myelodysplastic syndrome(MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML.
Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML).
Participants with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
No features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) on peripheral blood smear
Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AML
No features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) on peripheral blood smear
No features suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy
Subject has a diagnosis of primary acute myeloid leukemia (AML) or AML secondary to myelodysplastic syndrome (MDS) according to WHO classification (2008) as determined by pathology review at the treating institute.
Morphologically documented primary Acute Myeloid Leukemia (AML) or AML secondary to Myelodysplastic Syndrome (MDS), as defined by World Health Organization (WHO) criteria, as determined by pathology review at the study site.
Known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
Patients must not have known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
No Patients with treatment-related acute myeloid leukemia (AML) (t-AML)/myelodysplastic syndrome (MDS) or with features suggestive of AML/MDS
A history of other primary invasive malignancy that has not been in remission for at least 3 years or a current diagnosis of myelodysplastic syndrome (MDS) or an immature leukemia such as acute myeloid leukemia (AML)
Patients with myelodysplastic syndrome (MDS)/ treatment-related acute myeloid leukemia (t-AML) or with features suggestive of MDS/AML
Participants may not have any features suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicated
Patients with myelodysplastic syndrome/acute myeloid leukaemia.
Patients with myelodysplastic syndrome/acute leukemia or with features suggestive thereof.
Patients with treatment-related acute myeloid leukemia (AML) (t-AML)/myelodysplastic syndrome (MDS) or with features suggestive of AML/MDS. Prior allogeneic bone marrow transplant or double umbilical cord blood transplantation
No features suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicated
Treatment Group B (TGB): Acute Leukemia (Part 3 - acute myeloid leukemia [AML] only), myelodysplastic syndrome (MDS), myelodysplastic /myeloproliferative neoplasms (MDS/MPN) and myelofibrosis (MF)
De novo or secondary acute myeloid leukemia (AML) (post myelodysplastic syndrome [MDS] or myeloproliferative neoplasm [MPN] or after leukemogenic chemotherapy) according to WHO 2008 criteria For Part A:
Patient has any known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML).
Clonal cytogenetic abnormalities associated with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) on marrow examination
Untreated de novo or secondary acute myeloid leukemia (AML), including AML that has progressed from myelodysplastic syndrome (MDS), and histologically documented diagnosis
Participants with a previously documented diagnosis of myelodysplastic syndrome (or any dysplastic leukocyte morphology suggestive of myelodysplastic syndromes [MDS]) or acute myeloid leukemia
Subjects with treatment-related acute myeloid leukemia (AML) (t-AML)/myelodysplastic syndrome (MDS) or with features suggestive of AML/MDS
Histologically confirmed diagnosis of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) per 2016 World Health Organization (WHO) criteria
